Compare NFE & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NFE | IFRX |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 303.4M |
| IPO Year | 2018 | 2017 |
| Metric | NFE | IFRX |
|---|---|---|
| Price | $6.32 | $1.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $5.50 | ★ $6.25 |
| AVG Volume (30 Days) | ★ 2.4M | 577.8K |
| Earning Date | 04-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,504,037,000.00 | N/A |
| Revenue This Year | $110.34 | N/A |
| Revenue Next Year | $3.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $0.80 |
| 52 Week High | $16.90 | $2.95 |
| Indicator | NFE | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.51 | 42.95 |
| Support Level | $0.61 | $1.58 |
| Resistance Level | $16.90 | $2.38 |
| Average True Range (ATR) | 1.14 | 0.11 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 34.45 | 2.40 |
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.